DPx Holdings B.V, the result of a $2.65 billion transaction between JLL Partners and Royal DSM finalized in March, has completed the transaction to acquire Gallus BioPharmaceuticals, LLC, a leading St. Louis-based contract manufacturing company specializing in biologics.
DPx is a parent company to Patheon, which provides commercial manufacturing, pharmaceutical product development services for an array of solid and sterile dosage forms, and biologic and chemical drug substance development and manufacturing.
The acquisition will help DPx expand service offerings and dedicated biologics presence in the U.S.The two existing Gallus sites in St. Louis, Mo. and Princeton, N.J. will be the first Patheon biologic drug substance sites in the U.S. and compliment the two existing sites in Groningen, the Netherlands and Brisbane, Australia.
